Omega to stress company creation with largest fund

While Omega will still invest across the value chain of biopharma, its most recent and largest fund ever will allocate more resources and time to company creation.

On Friday, the firm announced the close of its Fund VII at $650 million, well above its $500 million target. It is also the latest example of capital pouring into biopharma venture firms: Omega Funds’ seventh fund is more than double the size of its $300 million fifth vehicle, and nearly 50% larger than the $438 million Fund VI, which closed in December 2019...